AAAAAA
Results: 101-125/3357
Authors:
Burgio, GR
Marseglia, GL
Citation: Gr. Burgio et Gl. Marseglia, Primum non nocere in vaccinology, VACCINE, 20, 2001, pp. S55-S57
Authors:
Miller, E
Salisbury, D
Ramsay, M
Citation: E. Miller et al., Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story, VACCINE, 20, 2001, pp. S58-S67
Authors:
Haase, M
Citation: M. Haase, Regulating vaccines involving new technologies to ensure safety and timelylicensure - the challenge, VACCINE, 20, 2001, pp. S68-S69
Authors:
Hessel, L
Citation: L. Hessel, Developing vaccines involving new technologies to ensure safety and timelylicensure - The industry perspective, VACCINE, 20, 2001, pp. S70-S72
Authors:
Paradiso, PR
Citation: Pr. Paradiso, Maternal immunization: the influence of liability issues on vaccine development, VACCINE, 20, 2001, pp. S73-S74
Authors:
Heijbel, H
Citation: H. Heijbel, Improving vaccine safety through the use of immunisation registers and barcode labelled vaccines, VACCINE, 20, 2001, pp. S75-S77
Authors:
Spier, RE
Citation: Re. Spier, Perception of risk of vaccine adverse events: a historical perspective, VACCINE, 20, 2001, pp. S78-S84
Authors:
Cookson, C
Citation: C. Cookson, Benefit and risk of vaccination as seen by the general public and the media, VACCINE, 20, 2001, pp. S85-S88
Authors:
Aston, R
Citation: R. Aston, The medical scientist working with the media for the public good, VACCINE, 20, 2001, pp. S89-S89
Authors:
Ernst, E
Citation: E. Ernst, Rise in popularity of complementary and alternative medicine: reasons and consequences for vaccination, VACCINE, 20, 2001, pp. S90-S93
Authors:
Gold, D
Citation: D. Gold, A look at new models to support vaccine research and development, VACCINE, 20, 2001, pp. S94-S95
Authors:
Duclos, P
Citation: P. Duclos, How to improve communication on vaccine safety at international level?, VACCINE, 20, 2001, pp. S96-S97
Authors:
Siegrist, CA
Desgrandchamps, D
Heininger, U
Vaudaux, B
Citation: Ca. Siegrist et al., How to improve communication on vaccine issues at the national level? INFOVAC-PED: an example from Switzerland, VACCINE, 20, 2001, pp. S98-S100
Authors:
Greco, M
Citation: M. Greco, The future of vaccines: an industrial perspective, VACCINE, 20, 2001, pp. S101-S103
Authors:
Vandersmissen, W
Citation: W. Vandersmissen, Business perspectives of a European vaccine manufacturer, VACCINE, 20, 2001, pp. S104-S106
Authors:
Ponvert, C
Ardelean-Jaby, D
Colin-Gorski, AM
Soufflet, B
Hamberger, C
de Blic, J
Scheinmann, P
Citation: C. Ponvert et al., Anaphylaxis to the 23-valent pneumococcal vaccine in child: a case-controlstudy based on immediate responses in skin tests and specific IgE determination, VACCINE, 19(32), 2001, pp. 4588-4591
Authors:
Puliyel, JM
Agarwal, KS
Abass, FA
Citation: Jm. Puliyel et al., Natural immunity to haemophilus influenza b in infancy in Indian children, VACCINE, 19(32), 2001, pp. 4592-4594
Authors:
Schneider, J
Langermans, JAM
Gilbert, SC
Blanchard, TJ
Twigg, S
Naitza, S
Hannan, CM
Aidoo, M
Crisanti, A
Robson, KJ
Smith, GL
Hill, AVS
Thomas, AW
Citation: J. Schneider et al., A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees, VACCINE, 19(32), 2001, pp. 4595-4602
Authors:
Becker, PD
Corral, RS
Guzman, CA
Grinstein, S
Citation: Pd. Becker et al., Adamantylamide dipeptide as effective immunoadjuvant in rabbits and mice, VACCINE, 19(32), 2001, pp. 4603-4609
Authors:
Gardner, EM
Bernstein, ED
Dran, S
Munk, G
Gross, P
Abrutyn, E
Murasko, DM
Citation: Em. Gardner et al., Characterization of antibody responses to annual influenza vaccination over four years in a healthy elderly population, VACCINE, 19(32), 2001, pp. 4610-4617
Authors:
Fiedler, M
Lu, MJ
Siegel, F
Whipple, J
Roggendorf, M
Citation: M. Fiedler et al., Immunization of woodchucks (Marmota monax) with hepatitis delta virus DNA vaccine, VACCINE, 19(32), 2001, pp. 4618-4626
Authors:
Niu, MT
Erwin, DE
Braun, MM
Citation: Mt. Niu et al., Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination, VACCINE, 19(32), 2001, pp. 4627-4634
Authors:
Jones, RL
Froeschle, JE
Atmar, RL
Matthews, JS
Sanders, R
Pardalos, J
Moeller, L
Chin, JE
Famula, M
Briggs, DJ
Citation: Rl. Jones et al., Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine, VACCINE, 19(32), 2001, pp. 4635-4643
Authors:
Lee, MS
Chien, LJ
Yueh, YY
Lu, CF
Citation: Ms. Lee et al., Measles seroepidemiology and decay rate of vaccine-induced measles IgG titers in Taiwan, 1995-1997, VACCINE, 19(32), 2001, pp. 4644-4651
Authors:
Livingston, BD
Newman, M
Crimi, C
McKinney, D
Chesnut, R
Sette, A
Citation: Bd. Livingston et al., Optimization of epitope processing enhances immunogenicity of multiepitopeDNA vaccines, VACCINE, 19(32), 2001, pp. 4652-4660